US 12,473,538 B2
DP04 polymerase variants
Mark Stamatios Kokoris, Bothell, WA (US); Marc Prindle, Seattle, WA (US); Jack Chase, Seattle, WA (US); Robert Busam, Seattle, WA (US); Michael Kovarik, Seattle, WA (US); Salka Keller, Shoreline, WA (US); Megan Murt, Seattle, WA (US); and Greg Thiessen, Seattle, WA (US)
Assigned to Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed by Roche Sequencing Solutions, Inc., Pleasanton, CA (US)
Filed on Jun. 2, 2023, as Appl. No. 18/328,078.
Application 18/328,078 is a continuation of application No. 16/610,460, granted, now 11,708,566, previously published as PCT/US2018/030972, filed on May 3, 2018.
Claims priority of provisional application 62/501,526, filed on May 4, 2017.
Prior Publication US 2024/0240161 A1, Jul. 18, 2024
Int. Cl. C12N 9/12 (2006.01); C12P 19/34 (2006.01); C12Q 1/6806 (2018.01)
CPC C12N 9/1252 (2013.01) [C12P 19/34 (2013.01); C12Q 1/6806 (2013.01); C12Y 207/07007 (2013.01)] 5 Claims
 
1. An isolated recombinant DNA polymerase, which recombinant DNA polymerase comprises an amino acid sequence that is at least 80% identical to amino acids 1-340 of SEQ ID NO:1, which recombinant DNA polymerase comprises mutations at amino acid positions 42, 56, 76, 78, 79, 82, 83, 86, 184, 189, 248, 289, 290, 291, 292, and 293, 297, 301, and 325, wherein the mutations are amino acid substitutions, wherein identification of positions is relative to wildtype DPO4 polymerase (SEQ ID NO:1), and which recombinant DNA polymerase exhibits polymerase activity.